The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSomero Regulatory News (SOM)

Share Price Information for Somero (SOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 327.50
Bid: 320.00
Ask: 335.00
Change: -2.50 (-0.76%)
Spread: 15.00 (4.688%)
Open: 327.50
High: 327.50
Low: 327.50
Prev. Close: 330.00
SOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

26 Jan 2022 07:00

RNS Number : 6274Z
Somero Enterprises Inc.
26 January 2022
 

26 January 2022

Somero Enterprises, Inc.

("Somero" or "the Company")

 

Trading Update

Strong finish to 2021 that exceeds previous guidance, healthy North American market drives results

Somero® provides the following update on trading for the financial year ended 31 December 2021 (the "Period").

The Board is pleased to report that with strong, profitable trading and excellent operational performance to deliver on customer orders in the fourth quarter, and in particular December, it now expects the Company to report 2021 revenue, EBITDA, and year-end cash ahead of guidance provided in the Company's 7 December 2021 trading update. The Board expects the Company to report revenue of approximately US $133.0m (+50% v 2020) ahead of previous guidance of US$ 130.0m, annual adjusted EBITDA of approximately US$ 48.0m (+83% v 2020) ahead of previous guidance of US$ 45.0m, and ending cash of approximately US$ 42.0m (+18% v 2020) ahead of previous guidance of US$ 39.0m. These estimates remain subject to any audit adjustments.

Leading Through Production Innovation

The Company made meaningful progress executing its product innovation growth strategy during the Period completing another active year of new product development. In June 2021, the Company launched the SkyStrip® high-rise structural shoring plywood removal solution, a disruptive product for the high-rise structural market. In 2021, the Company completed development of the S-PS50, a large boomed-screed that provides a mechanical alternative to the traditional manual process used to level concrete in tilt-up panel casting applications. Also in 2021, the Company completed development of the S-28EZ, the next generation large boomed-screed that replaces the S-22EZ.

The SkyScreed, SkyStrip and Somero Broom+CureTM, all recently launched products, contributed a combined US$ 1.8m to H2 2021 revenues and US$ 3.2m to the Period, representing an increase of US$ 1.0m in 2021 revenues compared to 2020. H2 2021 SkyScreed© sales were US$ 0.7m, an improvement from H1 2021 that reflects a modestly higher volume of jobsite product demonstrations, critical to the selling process, during the last six months of the year. The Company sees a significant opportunity in the high-rise structural market and expects continued, measured progress in penetrating it in 2022 and beyond. The Company also remains focused on identifying other opportunities to expand the product offering, such as with the recent Somero Broom+CureTM and just introduced S-PS50, to increase the Company's addressable market and to create a runway for long-term growth.

Regional and Product Breakdown

North America reported particularly strong trading results in H2 2021, representing improvement from H1 2021 revenues, to end a record-breaking year. In North America, full-year 2021 revenues grew an extraordinary 50% from the US$ 70.7m reported in 2020, robust trading performance that reflects the healthy, highly active US non-residential construction market in place throughout the year. Entering 2022, US non-residential market conditions remain positive, a view supported by customers reporting extended project backlogs that carry well into 2022. 

H2 2021 trading in Europe was comparable to H1 2021 and on a full-year basis in 2021 revenues grew approximately 40% from the US$ 8.7m reported in 2020, a meaningful contribution to growth for the year. As in the US, European non-residential market conditions remain positive entering 2022, similarly supported by reported customer project backlogs. 

H2 2021 trading in Australia increased compared to H1 2021, and increased significantly compared to H2 2020, to result in full-year 2021 revenues that grew more than 450% from the US$ 1.1m reported in 2020. This impressive performance was driven by an effective in-country direct sales and support team that capitalized on positive market conditions and favorable currency exchange rates to significantly improve the contribution from this market. Going forward, the Australian market is expected to provide a meaningful opportunity for growth from new products.

China reported H2 2021 trading that declined modestly from H1 2021 and full-year 2021 revenues that declined approximately 30% from the US$ 3.9m reported in 2020. The quality market segment in China, the Company's primary target, initially driven by western multi-national company development in the country, has been slower to grow than originally anticipated. In light of current market conditions and recent performance, the Company plans to reduce the cost structure of its China operations to begin 2022 while continuing to maintain consistency in supporting the customer base as we continue to evaluate our approach to target the long-term opportunity in this market.

H2 2021 trading activity in the remaining regions, specifically Latin America, the Middle East, and the Rest of World territories that includes India, was positive and these regions on a combined basis reported H2 2021 revenues that were comparable to H1 2021. Full year 2021 revenues, for these regions combined, grew approximately 38% from the US$ 4.3m reported in 2020.

On a product basis, while H2 2021 trading across all product categories increased significantly compared to H2 2020, the most notable, significant driver of H2 2021 trading was the Boomed-screed product line. H2 2021 boomed-screed revenues improved compared to H1 2021 and 2021 full-year revenues for this product line grew more than 100% from the US$ 31.7m reported in 2020. The robust 2021 performance in this product category reflects a high-level of large footprint, non-residential construction projects in the US that includes new warehousing required to support the rapid growth of e-commerce activity, factors that translated to an all-time record in unit sales of the Company's largest boomed-screed, the S-22EZ, in 2021.

Outlook

The Board is pleased with the strong finish to 2021 and looks forward to 2022 with confidence based on the strength of the US market, positive market conditions in Europe and Australia, targeted opportunities for growth from the other regions, and opportunities for growth from new products. Regarding new products, and taking a longer-term view, the Board recognizes the significant long-term value creation opportunity that comes from increasing the Company's addressable market by developing innovative solutions for new applications and market segments. As such, the Company remains committed to investment in product development, sales, and support resources to drive this effort, a necessary near-term investment and cost with longer-term benefit. With a combined view of these factors, the Board expects 2022 will be a highly profitable year with healthy cash generation, modest revenue growth, and EBITDA comparable to 2021 that reflects the planned investment in resources for future growth and the full-year impact of 2021 staffing additions required to support the growth of the business. 

Somero's final 2021 results announcement is scheduled for release on 9 March 2022.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as retained as part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended. Upon the publication of this Announcement, this inside information is now considered to be in the public domain.

 

Enquiries:

 

Somero Enterprises, Inc. www.somero.com

Jack Cooney, CEO +1 239 210 6500

John Yuncza, President

Enzo LiCausi, CFO

Howard Hohmann, EVP Sales

 

finnCap Ltd (NOMAD and Broker)

Matt Goode (Corporate Finance) +44 (0)20 7220 0500

Kate Bannatyne (Corporate Finance)

Tim Redfern/Richard Chambers (ECM)

 

Alma PR (Financial PR Advisor) somero@almapr.co.uk

David Ison +44 (0)20 3405 0205

Sam Modlin

Molly Gretton

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBKPBKKBKBDDB
Date   Source Headline
30th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
24th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
12th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
11th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
10th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
8th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
5th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
4th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Mar 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
20th Mar 20246:06 pmRNSTransaction in Own Shares and Total Voting Rights
19th Mar 20243:07 pmRNSRestricted Stock Units& Director/PDMR Shareholding
5th Mar 20247:00 amRNSFinal Results
7th Feb 20247:00 amRNSNotice of Investor Presentation
31st Jan 20247:00 amRNSTrading Update
5th Jan 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
4th Jan 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
13th Dec 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
11th Dec 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
1st Dec 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
15th Nov 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
14th Nov 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
26th Oct 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
19th Oct 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
6th Oct 20237:55 amRNSTransaction in Own Shares and Total Voting Rights
2nd Oct 20237:00 amRNSBoard Change
27th Sep 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
20th Sep 20238:49 amRNSTransaction in Own Shares and Total Voting Rights
18th Sep 20237:00 amRNSDirector/PDMR Shareholding & Change of NOMAD name
13th Sep 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
31st Aug 20237:00 amRNSInterim Results
29th Aug 20237:00 amRNSBoard Change
8th Aug 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
2nd Aug 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
31st Jul 20237:00 amRNSNotice of Investor Presentation
24th Jul 20237:00 amRNSTrading Update
5th Jul 20234:52 pmRNSTransaction in Own Shares and Total Voting Rights
4th Jul 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
27th Jun 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
20th Jun 20237:00 amRNSTrading Update
14th Jun 20233:46 pmRNSTransaction in Own Shares and Total Voting Rights
12th Jun 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
18th May 20233:10 pmRNSResult of AGM
17th May 20236:10 pmRNSTransaction in Own Shares and Total Voting Rights
17th May 20237:00 amRNSAGM Statement
12th May 20232:26 pmRNSTransaction in Own Shares and Total Voting Rights
4th May 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Apr 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
27th Apr 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
26th Apr 20236:15 pmRNSUpdate re: RSUs & Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.